Mobile

A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin L...

Update Il y a 4 ans
Reference: EUCTR2004-001091-40

A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin LAR Depot (20 and 30mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated with Carcinoid Syndrome

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the efficacy of lanreotide Autogel (90 and 120 mg), compared with Sandostatin LAR Depot (20 and 30 mg), in terms of the frequency of target symptom episodes, assessed by the change from baseline in the average daily number of episodes of the target symptom at Week 24.

Inclusion criteria

  • Treatment of clinical symptoms of carcinoid syndrome

Links